Prof Ray McDermott talks to ecancer at ESMO 2019 in Barcelona about the TRITON2 study.
This is for patients with DNA damage repair (DDR) -deficient metastatic castration-resistant
prostate cancer, and they were treated with rucaparib.
Prof McDermott outlines the positive results, and explains how testing for these DDR mutations is important, as well as the implications for this subset of patients.
Sign up to receive free email alerts for more videos like this.